Create Account | Sign In: Author or Forum

 
News  |  Journals  |  Conferences  |  Opinion  |  Articles  |  Forums  |  Twitter    
 
Category: Cardiology | Family Medicine | Geriatrics | Internal Medicine | Pharmacy | Conference News

Back to Journal Articles

ATVB: Drug Combo May Be Best for Plaque Regression

Last Updated: April 29, 2011.

 

Atorvastatin plus etidronate reduces aortic plaques more than atorvastatin alone

Share |

Comments: (0)

Tell-a-Friend

 

  Related
 
The combination of atorvastatin plus etidronate appears to be superior to atorvastatin alone for causing the regression of thoracic and abdominal aortic plaques, according to research presented at the Arteriosclerosis, Thrombosis and Vascular Biology 2011 Scientific Sessions, held from April 28 to 30 in Chicago.

FRIDAY, April 29 (HealthDay News) -- The combination of atorvastatin plus etidronate appears to be superior to atorvastatin alone for causing the regression of thoracic and abdominal aortic plaques, according to research presented at the Arteriosclerosis, Thrombosis and Vascular Biology 2011 Scientific Sessions, held from April 28 to 30 in Chicago.

In a prospective, open-label, blind-end point study, Tetsuya Kawahara, M.D., of the University of Calgary in Canada, and colleagues randomized 251 patients with asymptomatic hypercholesterolemia to receive 20 mg of atorvastatin per day or 20 mg of atorvastatin plus 400 mg of etidronate per day. The primary end point was the change of atherosclerotic plaques after 24 months of treatment.

The investigators found that the mean low-density lipoprotein cholesterol level was reduced by 44 percent in the combination-therapy group and by 45 percent in the atorvastatin group (P < 0.001 versus baseline for both groups). Maximal vessel wall thickness in the thoracic aorta was reduced by 13 percent in the combination-therapy group and by 15 percent in the atorvastatin-alone group (P = 0.587). However, over 24 months, the combination-therapy group experienced higher rates of reduction of maximal vessel wall thickness in the abdominal aorta than those in the atorvastatin group (1 versus 12 percent; P < 0.001). The incidence of major cardiovascular events was lower in the combination therapy group than in the atorvastatin group (1 versus 5 percent; P = 0.049).

"This trial showed that atorvastatin plus etidronate combination therapy caused a significant regression of both thoracic and abdominal aortic plaques, whereas atorvastatin monotherapy did [so] only [for] thoracic aortic plaques. In addition, the combination therapy might be superior to atorvastatin monotherapy in decreasing the incidence of cardiovascular events," the authors write.

Presentation
More Information

Copyright © 2011 HealthDay. All rights reserved.


Previous: SBM: VEGF Expression Tied to Poor Psychological Function Next: Obese White Teens May Have Increased Risk of Depression

Reader comments on this article are listed below. Review our comments policy.


Submit your opinion:

Name:

Email:

Location:

URL:

Remember my personal information

Notify me of follow-up comments?

advertisement.gif (61x7 -- 0 bytes)
 

Are you a Doctor, Pharmacist, PA or a Nurse?

Join the Doctors Lounge online medical community

  • Editorial activities: Publish, peer review, edit online articles.

Doctors Lounge Membership Application

 
     

 advertisement.gif (61x7 -- 0 bytes)

 

 

Useful Sites
MediLexicon
  Tools & Services: Follow DoctorsLounge on Twitter Follow us on Twitter | RSS News | Newsletter | Contact us
Copyright © 2001-2014
Doctors Lounge.
All rights reserved.

Medical Reference:
Diseases | Symptoms
Drugs | Labs | Procedures
Software | Tutorials

Advertising
Links | Humor
Forum Archive
CME | Conferences

Privacy Statement
Terms & Conditions
Editorial Board
About us | Email

This website is certified by Health On the Net Foundation. Click to verify. This site complies with the HONcode standard for trustworthy health information:
verify here.